Valuation : Interpace Biosciences, Inc.

Market Cap 36.4M 31.3M 29.54M 26.91M 50.3M 3.48B 50.75M 352M 135M 1.77B 137M 134M 5.61B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 35.08M 30.17M 28.46M 25.93M 48.47M 3.35B 48.91M 339M 130M 1.7B 132M 129M 5.4B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+1.08%
1 week+0.92%
Current month-13.21%
1 month-22.71%
3 months-25.47%
6 months-23.60%
Current year+6.81%
1 week 6.5
Extreme 6.5
6.8
1 month 6.45
Extreme 6.45
8.5
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
50.25
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+0.92%+54.59%+25.14% 36.4M
-1.26%-0.47%+92.08%+501.73% 47.01B
-4.40%-7.40%+12.46%+50.98% 24.89B
-1.91%-2.76%-15.37%-38.61% 6.86B
+4.81%-0.46%+4.15%+146.45% 5.85B
-0.09%+2.05%+16.68%+72.52% 3.35B
-2.91%-3.92%-31.85%+1,713.39% 2.5B
-0.28%+0.86%+135.43%+29.58% 2.26B
+3.00%+4.28%+33.33%+47.09% 2.24B
-2.03%-1.81%-18.64%-56.41% 1.78B
Average -0.39%-1.15%+28.29%+249.19% 9.68B
Weighted average by Cap. -1.64%-1.08%+50.47%+310.54%

Financials

2024 2025
Net sales 46.93M 40.36M 38.08M 34.69M 64.84M 4.49B 65.43M 453M 175M 2.28B 176M 172M 7.23B 38.73M 33.31M 31.43M 28.63M 53.52M 3.7B 54M 374M 144M 1.88B 145M 142M 5.97B
Net income 6.7M 5.76M 5.44M 4.95M 9.26M 641M 9.35M 64.77M 24.93M 325M 25.17M 24.62M 1.03B 24.58M 21.13M 19.94M 18.17M 33.96M 2.35B 34.27M 237M 91.4M 1.19B 92.28M 90.27M 3.79B
Net Debt 4.4M 3.78M 3.57M 3.25M 6.07M 420M 6.13M 42.47M 16.35M 213M 16.5M 16.14M 677M -1.32M -1.14M -1.07M -977K -1.83M -126M -1.84M -12.78M -4.92M -64.11M -4.96M -4.86M -204M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
10/09/26 $6.570 +1.08% 2,827
09/09/26 $6.500 -5.97% 271
04/09/26 $6.913 +6.18% 3,270
03/09/26 $6.510 -6.73% 9,471
02/09/26 $6.980 -0.29% 5,330

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXGD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!